HRA meeting
March 21-22, 2023

IBD Therapeutics Incubator
Andrés Hurtado-Lorenzo, Ph.D.
Vice President, Translational Research & IBD Ventures
Today’s Presentation

**IBD Therapeutics Incubator**

Innovative funding mechanism for drug discovery in IBD

*IBD: Inflammatory Bowel Diseases*
IBD Ventures
Investments to accelerate development of solutions for IBD patients

IBD Ventures

VENTURE INVESTMENTS
Advance new product opportunities
Industry
Academia

THERAPEUTICS INCUBATOR
Create new therapeutic opportunities
Academia

IBD ventures
CROHN’S & COLITIS FOUNDATION
IBD Ventures
Investments to accelerate development of solutions for IBD patients

Today’s Focus

VENTURE INVESTMENTS
Advance new product opportunities
Industry, Academia

THERAPEUTICS INCUBATOR
Create new therapeutic opportunities
Academia
Therapeutics Discovery Continuum

Basic Research
- Target Identification
- Target Validation

Drug Discovery & Development
- Drug Candidate Discovery
- Drug Candidate Optimization
- Preclinical Development
- Clinical Development

Foundation’s funded research

ACADEMIA

INDUSTRY

Animals, Safety, Efficacy, Pharmacology
Human Clinical Trials, Safety, Efficacy, Pharmacology
IBD Therapeutics Incubator
Bridging the gap between the bench & bedside
IBD Therapeutics Incubator

Providing resources to accelerate drug discovery – R&D led by Foundation’s scientific staff

Academic PI (Target) + CRO (Drug discovery) = New PAI-1 inhibitor candidates

Pharma and VC Partnerships
- Development
- Commercialization

New IP
IBD Therapeutics Incubator

Proof of Concept Study
PAI-1 Target for Drug Discovery

Drug target discovered through the Foundation’s Genetics Initiative

Drug Target: PAI-1 (Elevated in IBD)

Mode of Action: Inhibition of PAI-1 leads to mucosal healing

Drug Type: PAI-1 Inhibitor

Figure modified from Honig et al, 2020. Inflamm. Bowel. Dis.

Dr. Stappenbeck
How to translate these findings into a therapeutic opportunity for patients?
IBD Therapeutics Incubator: PAI-1 Drug Discovery

Goal
Identify potent, safe gut-targeted PAI-1 inhibitors

Challenge
Prior PAI-1 systemic inhibitors have safety liabilities
Outcomes - Efficacious Drug-Like PAI-1 Inhibitor Discovered

Drug-like inhibitor of PAI-1 (CCF104) identified
- Gut restricted
- Potent
- Heal gut ulcers (mucosal healing)
- Improves colitis end points

Ongoing support by the IBD Therapeutics Incubator
- Identification of PD biomarkers to support future clinical development
- Presentation to Venture Capital

Follow-on Funding & Spin-off
- Multi-million follow-on funding raised
- New company created

Successful proof of concept
The Foundation’s Therapeutics Incubator effectively accelerates drug discovery for promising therapeutic targets
Milestones

- **First Project (Proof of Concept)**
  - (Discovered gut targeted lead compounds for PAI-1 inhibition)
  - 2019 – Present

- **RFP** (2 new projects starting in 2023)

- **Generate new product opportunities**
IBD Therapeutics Incubator

RFP Launched - July 20th 2022

- Worldwide outreach
- Seeking new, differentiated and validated drug targets
- Incubator will provide drug discovery & development resources
- Milestone based funding

IBD Therapeutics Request for Proposals
Foundation’s Drug Discovery & Development Expertise

Jennifer Swantek, PhD
Director, IBD Therapeutics Incubator

Russel Wyborski, PhD
Director, IBD Venture Investments

Andrés Hurtado-Lorenzo, PhD
VP, Translational Research & IBD Ventures

60 years of discovery and development experience
Translating innovative academic research into effective IBD drug discovery & development
Thank you !